Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Michael Palladinetti, global head of business development and licensing at Sanofi, told delegates attending Bio Europe Spring in Barcelona, Spain last week that history has shown us time and time again that no one has the monopoly on the next wave of innovation. Citing the recent GLP-1 wave, Palladinetti said the industry has a bit of fear of missing out (FOMO) and paid kudos to Lily and Novo for staying in the space. He added how innovation is also very difficult and that industry players need to have a broad view. Both firms are pioneers in the diabetes space, having launched their own versions of insulin over 100 years ago
Stark J et al
Given no known difference in efficacy on antidepressant effects, bupropion should be considered the best initial choice of antidepressant in depressed overweight and obese patients when no known contraindications are present
The 24.2% weight loss at 12mg was the headline number, but the data at lower doses is equally informative
It can manifest itself in a variety of ways
US$ 20.46
US$ 29.61
US$ 24.46
US$ 28.53
US$ 27.43
